Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- PMID: 27861837
- DOI: 10.1111/head.12962
Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Abstract
Background: Though migraine, particularly migraine with aura, is a cardiovascular (CV) risk factor, the scope and distribution of cardiovascular disease in representative samples of people with migraine are not known. This is important because many widely used acute migraine treatments, including triptans, ergot alkaloids, and nonsteroidal anti-inflammatory drugs, carry precautions, warnings, or contraindications for use in persons with CV disease.
Objectives: To assess the scope and distribution of cardiovascular events, conditions, and procedures in persons with episodic migraine in a representative sample of the US population, using data from the American Migraine Prevalence and Prevention (AMPP) Study.
Methods: Eligible subjects completed the 2009 AMPP survey, met ICHD-3beta criteria for migraine, and had a headache frequency of less than 15 days per month (episodic migraine). A survey on cardiovascular events (ie, myocardial infarction), conditions (ie, angina), and procedures (ie, carotid endarterectomy) was adopted from the Women's Health Study and the Physician's Health Studies. Cardiovascular events and conditions were defined by participant reports of having both experienced and received a physician diagnosis for a particular event or condition. The distribution of CV events, conditions, and procedures was summarized for the entire migraine sample and in groups defined by gender and age (22-39, 40-59, and ≥60). To assess the numbers of persons with episodic migraine in the US, we applied age and gender stratified estimates of migraine prevalence to the 2015 Census data. To estimate the number of cardiovascular events, conditions, and procedures in the US migraine population, we applied age and gender stratified event rates to the number of persons with episodic migraine in each stratum.
Results: The 2009 AMPP Study survey was returned by 11,792 study participants out of 16,983 (64.9% response rate), including 6723 individuals who met study criteria for episodic migraine (5227 women and 1496 men). Among 22-39 year olds with episodic migraine, 3.4% reported having received a physician diagnosis of CV events or conditions and 1.1% reported undergoing CV related procedures. Among 40-59 year olds, 10.2% reported having received a physician diagnosis of CV events or conditions and 3.5% reported CV related procedures. For those age 60 or older, 22.3% reported CV events or conditions and 8.8% reported CV procedures. Prevalence of events, conditions, and procedures was higher in men than women and also in older age groups. However, the absolute number of CV events, procedures, and conditions was greater for women than men due to the higher population prevalence of episodic migraine in women. We projected that 2.0 million women and 665,000 men in the US had episodic migraine and a history of one or more CV event, condition, or procedure. By age group, it is estimated that 579,000 among those aged 22-39, 1.37 million of those aged 40-59, and 696,000 of those 60 and older with episodic migraine have ever had at least one CV event, procedure, or condition.
Conclusion: Based on these analyses, we estimate that there are roughly 2.6 million people with episodic migraine aged 22 and older in the US with one or more prior CV event, condition, or procedure. For this group, cardiovascular contraindications to many migraine-specific acute migraine therapies may make treatment challenging.
Keywords: AMPP study; cardiovascular; episodic migraine; myocardial infarction; stroke; triptan.
© 2016 American Headache Society.
Similar articles
-
Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.Headache. 2017 Nov;57(10):1507-1521. doi: 10.1111/head.13179. Epub 2017 Oct 9. Headache. 2017. PMID: 28990165
-
Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.Headache. 2015 Jun;55(6):825-39. doi: 10.1111/head.12556. Epub 2015 Apr 17. Headache. 2015. PMID: 25881857
-
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.Headache. 2016 Sep;56(8):1280-9. doi: 10.1111/head.12878. Epub 2016 Jun 28. Headache. 2016. PMID: 27349336 Free PMC article.
-
The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.Headache. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7. Headache. 2013. PMID: 23470015 Review.
-
Tracing transformation: chronic migraine classification, progression, and epidemiology.Neurology. 2009 Feb 3;72(5 Suppl):S3-7. doi: 10.1212/WNL.0b013e3181974b19. Neurology. 2009. PMID: 19188564 Review.
Cited by
-
Migraine and increased cardiovascular disease risk: interaction with traditional risk factors and lifestyle factors.J Headache Pain. 2025 Apr 28;26(1):92. doi: 10.1186/s10194-025-02002-6. J Headache Pain. 2025. PMID: 40295899 Free PMC article.
-
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.JAMA. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939. JAMA. 2021. PMID: 34128998 Free PMC article.
-
A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.Cephalalgia. 2022 Oct;42(11-12):1255-1264. doi: 10.1177/03331024221104180. Epub 2022 May 31. Cephalalgia. 2022. PMID: 35642092 Free PMC article.
-
Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial.Front Physiol. 2017 Dec 19;8:1086. doi: 10.3389/fphys.2017.01086. eCollection 2017. Front Physiol. 2017. PMID: 29311997 Free PMC article.
-
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30. Cephalalgia. 2019. PMID: 31146544 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous